Windward Bio Group Ag (WWB) closed at $28.50 on November 13, 2026, on volume of 1,245,888 shares.
Data as of November 13, 2026.
No headlines found.
No press releases found.
No news found.
Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
Windward Bio Group Ag trades on the NASDAQ stock market under the symbol WWB.
As of November 13, 2026, WWB stock price climbed to $28.50 with 1,245,888 million shares trading.
WWB has a market cap of $1.65 billion. This is considered a Small Cap stock.
